Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3431986 | 0.76 | USP2 (0.57) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL9549501 | 0.76 | USP2 (0.57) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL5682504 | 0.74 | USP2 (0.55) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL1696945 | 0.74 | USP2 (0.55) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL9615626 | 0.73 | USP2 (0.70) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL15273117 | 0.73 | USP2 (0.70) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| Glucosaminic Acid SCHEMBL396940 | 0.71 | USP2 (1.00) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| Glucosaminic Acid SCHEMBL5290846 | 0.71 | USP2 (1.00) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| Glucosaminic Acid SCHEMBL17830012 | 0.71 | USP2 (1.00) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| Glucosaminic Acid SCHEMBL13984380 | 0.71 | USP2 (1.00) | USP2SLCO1B1LMNAL3MBTL1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 725 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140997-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF | ACCESS TO ADVANCED HEALTH INSTITUTE | 2024-05-02 | — | — | US | claimed |
| US-11897922-B2 | Immunogenic compositions comprising Mycobacterium tuberculosis polypeptides and fusions thereof | ACCESS TO ADVANCED HEALTH INSTITUTE (US) | 2024-02-13 | — | — | US | claimed |
| US-20220017578-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF | ACCESS TO ADVANCED HEALTH INSTITUTE | 2022-01-20 | — | — | US | claimed |
| US-11091521-B2 | Immunogenic compositions comprising Mycobacterium tuberculosis polypeptides and fusions thereof | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2021-08-17 | — | — | US | claimed |
| US-20210060052-A1 | IN SITU METHODS OF INDUCING OF IMMUNE RESPONSE | ATOSSA THERAPEUTICS, INC. (US) | 2021-03-04 | — | — | US | claimed |
| EP-3765007-A1 | IN SITU METHODS OF INDUCING OF IMMUNE RESPONSE | Atossa Therapeutics, Inc. (US) | 2021-01-20 | — | — | EP | claimed |
| WO-2019177991-A1 | IN SITU METHODS OF INDUCING OF IMMUNE RESPONSE | ATOSSA GENETICS, INC. (US) | 2019-09-19 | — | — | WO | claimed |
| US-20180170975-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2018-06-21 | — | — | US | claimed |
| US-9822152-B2 | Immunogenic compositions comprising Mycobacterium tuberculosis polypeptides and fusions thereof | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2017-11-21 | — | — | US | claimed |
| CN-106456546-A | Liposomal compositions for mucosal delivery | 葛兰素史密丝克莱恩生物有限公司 | 2017-02-22 | — | — | CN | claimed |
| US-20120093914-A1 | IMPLANTABLE LIPOSOME EMBEDDED MATRIX COMPOSITION, USES THEREOF, AND POLYCAPROLACTONE PARTICLES AS SCAFFOLDS FOR TISSUE REGENERATION | MOMA THERAPEUTICS (US) | 2012-04-19 | — | — | US | claimed |
| EP-2370112-A2 | IMPLANTABLE LIPOSOME EMBEDDED MATRIX COMPOSITION, USES THEREOF, AND POLYCAPROLACTONE PRATICLES AS SCAFFOLDS FOR TISSUE REGENERATION | Schubert Holdings LLC (US) | 2011-10-05 | — | — | EP | claimed |
| WO-2010060104-A2 | IMPLANTABLE LIPOSOME EMBEDDED MATRIX COMPOSITION, USES THEREOF, AND POLYCAPROLACTONE PRATICLES AS SCAFFOLDS FOR TISSUE REGENERATION | MOMA THERAPEUTICS (US) | 2010-05-27 | — | — | WO | claimed |
| US-20030228279-A1 | Compositions and methods for viral delivery | CORIXA CORPORATION | 2003-12-11 | — | — | US | claimed |
| WO-2003037275-A2 | COMPOSITIONS AND METHODS FOR VIRAL DELIVERY | CORIXA CORPORATION (US) | 2003-05-08 | — | — | WO | claimed |
| CN-118302447-A | Anti-ILT 4 and anti-PD-1 bispecific constructs | 塞尔德克斯医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2024130341-A1 | BENZIMIDAZOLE DERIVATIVES FOR THE MODULATION OF STING | Aculeus Therapeutics Pty Ltd (AU) | 2024-06-27 | — | — | WO | disclosed |
| CN-1265112-A | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors | KRIKSA LTD (US) | 2000-08-30 | — | — | CN | disclosed |
| EP-0983286-A1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050399-A1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140997-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF | FNTB, CD74, MICA | USP2 2951/4885SLCO1B1 4107/4885LMNA 1875/4885 |
| US-11091521-B2 | Immunogenic compositions comprising Mycobacterium tuberculosis polypeptides and fusions thereof | FNTB, CD74, MICA | USP2 2951/4885SLCO1B1 4107/4885LMNA 1875/4885 |
| US-20220017578-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF | FNTB, MICA, CD74 | USP2 2997/4885SLCO1B1 4050/4885LMNA 2248/4885 |
| US-11897922-B2 | Immunogenic compositions comprising Mycobacterium tuberculosis polypeptides and fusions thereof | FNTB, CD74, MICA | USP2 3010/4885SLCO1B1 4076/4885LMNA 1991/4885 |
| US-20030228279-A1 | Compositions and methods for viral delivery | DDOST, ASGR1, STT3A | USP2 3708/4885SLCO1B1 3024/4885LMNA 2111/4885 |
| US-20120093914-A1 | IMPLANTABLE LIPOSOME EMBEDDED MATRIX COMPOSITION, USES THEREOF, AND POLYCAPROLACTONE PARTICLES AS SCAFFOLDS FOR TISSUE REGENERATION | MIF, CD14, MITF | USP2 1057/4885SLCO1B1 4133/4885LMNA 1490/4885 |
| US-20180170975-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF | FNTB, CD74, MICA | USP2 2951/4885SLCO1B1 4107/4885LMNA 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.